- Home
- CLLS vs NMRA Comparison
CLLS vs NMRA Comparison
Compare CLLS & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- NMRA
- Stock Information
- Founded
- CLLS 1999
- NMRA 2019
- Country
- CLLS France
- NMRA United States
- Employees
- CLLS N/A
- NMRA N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- NMRA
- Sector
- CLLS Health Care
- NMRA
- Exchange
- CLLS Nasdaq
- NMRA Nasdaq
- Market Cap
- CLLS 299.0M
- NMRA 268.5M
- IPO Year
- CLLS 2007
- NMRA 2023
- Fundamental
- Price
- CLLS $2.85
- NMRA $1.62
- Analyst Decision
- CLLS Buy
- NMRA Buy
- Analyst Count
- CLLS 1
- NMRA 8
- Target Price
- CLLS $4.00
- NMRA $7.14
- AVG Volume (30 Days)
- CLLS 199.3K
- NMRA 931.0K
- Earning Date
- CLLS 08-04-2025
- NMRA 08-06-2025
- Dividend Yield
- CLLS N/A
- NMRA N/A
- EPS Growth
- CLLS N/A
- NMRA N/A
- EPS
- CLLS N/A
- NMRA N/A
- Revenue
- CLLS $63,438,000.00
- NMRA N/A
- Revenue This Year
- CLLS N/A
- NMRA N/A
- Revenue Next Year
- CLLS $4.90
- NMRA N/A
- P/E Ratio
- CLLS N/A
- NMRA N/A
- Revenue Growth
- CLLS 223.09
- NMRA N/A
- 52 Week Low
- CLLS $1.10
- NMRA $0.61
- 52 Week High
- CLLS $3.24
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- CLLS 59.27
- NMRA 51.72
- Support Level
- CLLS $2.71
- NMRA $1.56
- Resistance Level
- CLLS $3.08
- NMRA $1.78
- Average True Range (ATR)
- CLLS 0.20
- NMRA 0.12
- MACD
- CLLS -0.03
- NMRA -0.03
- Stochastic Oscillator
- CLLS 61.67
- NMRA 58.97
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.